BioXcel Therapeutics, Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
BioXcel Therapeutics, Inc. (BTAI) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $4.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.83M, a 20.79% decline year-over-year.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $2.21M.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $8.01M.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.08M.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $6.97M.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$4.33M.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$3.22M, a 124.70% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $13.03M, a 168.66% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.05M 10-Q · filed 2026-08-13 | $12.06M derived: sum of 3 quarters · filed 2026-08-13 | $10.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-15 | $10.23M derived: sum of 2 quarters · filed 2026-05-15 | $9.14M derived: sum of 3 quarters · filed 2026-05-15 | $11.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $6.93M derived: sum of 2 quarters · filed 2026-03-27 | $9.24M derived: sum of 3 quarters · filed 2026-08-13 | $6.97M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2026-08-13 | -$1.04M 10-Q · filed 2025-11-12 | -$4.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $45.00K 10-Q · filed 2026-08-13 | -$3.29M derived: sum of 3 quarters · filed 2026-08-13 | -$4.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.27M 10-Q · filed 2026-05-15 | -$5.60M derived: sum of 2 quarters · filed 2026-05-15 | -$7.26M derived: sum of 3 quarters · filed 2026-05-15 | -$11.42M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$4.99M derived: sum of 2 quarters · filed 2026-03-27 | -$9.15M derived: sum of 3 quarters · filed 2026-03-27 | -$4.33M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.82M derived: sum of 2 quarters · filed 2025-11-12 | -$997.00K 10-Q · filed 2025-11-12 | -$13.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$4.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $664.00K 10-Q · filed 2025-08-12 | -$11.65M derived: sum of 3 quarters · filed 2025-08-12 | -$4.40M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.83M 10-Q · filed 2025-05-12 | -$7.49M derived: sum of 2 quarters · filed 2025-05-12 | -$236.00K derived: sum of 3 quarters · filed 2025-05-12 | $6.26M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$5.06M derived: sum of 2 quarters · filed 2025-03-28 | $1.44M derived: sum of 3 quarters · filed 2025-03-28 | -$3.22M 10-K · filed 2025-03-28 |
| 2023-09-30 | $7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $13.75M derived: sum of 2 quarters · filed 2024-11-14 | $9.10M 10-Q · filed 2024-11-14 | $18.33M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.84M 10-Q · filed 2024-08-06 | $11.08M derived: sum of 3 quarters · filed 2024-08-06 | $11.56M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$4.65M 10-Q · filed 2024-05-09 | $4.58M derived: sum of 2 quarters · filed 2024-05-09 | $5.06M derived: sum of 3 quarters · filed 2024-05-09 | $9.05M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $9.71M derived: sum of 2 quarters · filed 2024-03-22 | $13.71M derived: sum of 3 quarters · filed 2024-03-22 | $13.03M 10-K · filed 2024-03-22 |
| 2022-09-30 | $480.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.47M derived: sum of 2 quarters · filed 2023-11-14 | $3.79M 10-Q · filed 2023-11-14 | $5.84M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.31M 10-Q · filed 2023-08-14 | $5.36M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$676.00K 10-Q · filed 2023-05-09 | $1.37M derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $4.85M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |